254 related articles for article (PubMed ID: 35013029)
1. Possibilities and challenges of small molecule organic compounds for the treatment of repeat diseases.
Nakatani K
Proc Jpn Acad Ser B Phys Biol Sci; 2022; 98(1):30-48. PubMed ID: 35013029
[TBL] [Abstract][Full Text] [Related]
2. CAG repeat RNA as an auxiliary toxic agent in polyglutamine disorders.
Wojciechowska M; Krzyzosiak WJ
RNA Biol; 2011; 8(4):565-71. PubMed ID: 21593608
[TBL] [Abstract][Full Text] [Related]
3. RNA FISH for detecting expanded repeats in human diseases.
Urbanek MO; Krzyzosiak WJ
Methods; 2016 Apr; 98():115-123. PubMed ID: 26615955
[TBL] [Abstract][Full Text] [Related]
4. No association of the SCA1 (CAG)31 allele with Huntington's disease, myotonic dystrophy type 1 and spinocerebellar ataxia type 3.
Hellenbroich Y; Kaulich M; Opitz S; Schwinger E; Zühlke C
Psychiatr Genet; 2004 Jun; 14(2):61-3. PubMed ID: 15167689
[TBL] [Abstract][Full Text] [Related]
5. Length-dependent CTG·CAG triplet-repeat expansion in myotonic dystrophy patient-derived induced pluripotent stem cells.
Du J; Campau E; Soragni E; Jespersen C; Gottesfeld JM
Hum Mol Genet; 2013 Dec; 22(25):5276-87. PubMed ID: 23933738
[TBL] [Abstract][Full Text] [Related]
6. RNA-mediated neuromuscular disorders.
Ranum LP; Cooper TA
Annu Rev Neurosci; 2006; 29():259-77. PubMed ID: 16776586
[TBL] [Abstract][Full Text] [Related]
7. [Effect of Small Molecules on Repeat RNA Toxicity in Animal Models].
Nakatani K
Brain Nerve; 2022 Jan; 74(1):85-91. PubMed ID: 34992179
[TBL] [Abstract][Full Text] [Related]
8. Coincident trinucleotide repeat expansions in a patient with myotonic dystrophy type 1 and spinocerebellar ataxia.
Kolb SJ; Kissel JT
J Clin Neuromuscul Dis; 2008 Sep; 10(1):22-3. PubMed ID: 18772697
[TBL] [Abstract][Full Text] [Related]
9. Microsatellite repeat instability and neurological disease.
Brouwer JR; Willemsen R; Oostra BA
Bioessays; 2009 Jan; 31(1):71-83. PubMed ID: 19154005
[TBL] [Abstract][Full Text] [Related]
10. CAG repeats mimic CUG repeats in the misregulation of alternative splicing.
Mykowska A; Sobczak K; Wojciechowska M; Kozlowski P; Krzyzosiak WJ
Nucleic Acids Res; 2011 Nov; 39(20):8938-51. PubMed ID: 21795378
[TBL] [Abstract][Full Text] [Related]
11. Triplet repeat RNA structure and its role as pathogenic agent and therapeutic target.
Krzyzosiak WJ; Sobczak K; Wojciechowska M; Fiszer A; Mykowska A; Kozlowski P
Nucleic Acids Res; 2012 Jan; 40(1):11-26. PubMed ID: 21908410
[TBL] [Abstract][Full Text] [Related]
12. Cellular toxicity of expanded RNA repeats: focus on RNA foci.
Wojciechowska M; Krzyzosiak WJ
Hum Mol Genet; 2011 Oct; 20(19):3811-21. PubMed ID: 21729883
[TBL] [Abstract][Full Text] [Related]
13. A cyclic pyrrole-imidazole polyamide reduces pathogenic RNA in CAG/CTG triplet repeat neurological disease models.
Ikenoshita S; Matsuo K; Yabuki Y; Kawakubo K; Asamitsu S; Hori K; Usuki S; Hirose Y; Bando T; Araki K; Ueda M; Sugiyama H; Shioda N
J Clin Invest; 2023 Nov; 133(22):. PubMed ID: 37707954
[TBL] [Abstract][Full Text] [Related]
14. The unstable repeats--three evolving faces of neurological disease.
Nelson DL; Orr HT; Warren ST
Neuron; 2013 Mar; 77(5):825-43. PubMed ID: 23473314
[TBL] [Abstract][Full Text] [Related]
15. Dominantly inherited, non-coding microsatellite expansion disorders.
Ranum LP; Day JW
Curr Opin Genet Dev; 2002 Jun; 12(3):266-71. PubMed ID: 12076668
[TBL] [Abstract][Full Text] [Related]
16. Triplet repeats, RNA secondary structure and toxic gain-of-function models for pathogenesis.
Galvão R; Mendes-Soares L; Câmara J; Jaco I; Carmo-Fonseca M
Brain Res Bull; 2001 Oct-Nov 1; 56(3-4):191-201. PubMed ID: 11719250
[TBL] [Abstract][Full Text] [Related]
17. Patterns of CAG repeat instability in the central nervous system and periphery in Huntington's disease and in spinocerebellar ataxia type 1.
Mouro Pinto R; Arning L; Giordano JV; Razghandi P; Andrew MA; Gillis T; Correia K; Mysore JS; Grote Urtubey DM; Parwez CR; von Hein SM; Clark HB; Nguyen HP; Förster E; Beller A; Jayadaev S; Keene CD; Bird TD; Lucente D; Vonsattel JP; Orr H; Saft C; Petrasch-Parwez E; Wheeler VC
Hum Mol Genet; 2020 Aug; 29(15):2551-2567. PubMed ID: 32761094
[TBL] [Abstract][Full Text] [Related]
18. Identification of Plant-derived Alkaloids with Therapeutic Potential for Myotonic Dystrophy Type I.
Herrendorff R; Faleschini MT; Stiefvater A; Erne B; Wiktorowicz T; Kern F; Hamburger M; Potterat O; Kinter J; Sinnreich M
J Biol Chem; 2016 Aug; 291(33):17165-77. PubMed ID: 27298317
[TBL] [Abstract][Full Text] [Related]
19. Precise small-molecule cleavage of an r(CUG) repeat expansion in a myotonic dystrophy mouse model.
Angelbello AJ; Rzuczek SG; Mckee KK; Chen JL; Olafson H; Cameron MD; Moss WN; Wang ET; Disney MD
Proc Natl Acad Sci U S A; 2019 Apr; 116(16):7799-7804. PubMed ID: 30926669
[TBL] [Abstract][Full Text] [Related]
20. Increased (CTG/CAG)(n) lengths in myotonic dystrophy type 1 and Machado-Joseph disease genes in idiopathic azoospermia patients.
Pan H; Li YY; Li TC; Tsai WT; Li SY; Hsiao KM
Hum Reprod; 2002 Jun; 17(6):1578-83. PubMed ID: 12042281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
